Chang Mei-Hwei is the first person in the world to prove that the hepatitis B vaccine can prevent liver cancer in children. She found that the RNA-binding gene on the Y chromosome is the exclusive oncogene of liver cancer. Various studies of her have filled in the missing parts of international papers that lack long-term natural history of childhood hepatitis B virus infection, especially the relationship between the virus and the hosts. Chang Mei-Hwei has made a deep impact on childhood hepatitis and liver cancer research, and extended the concept of this anti-cancer vaccine to other cancers (such as cervical cancer, gastric cancer, and more), hoping that other infectious cancers can be prevented.

From hepatitis B to hepatitis C, she is a model female scientist in both teaching and research. Wu Lee Yan-Hwa and four Yang-Ming University professors (Ting Ling-Pai, Liu Wu-Che, Lo Shih-Cheng, Chu Kuang-Pang) jointly participated in the completion of the selection of hepatitis B virus surface antigen gene fragments and small-scale development of gene recombination for the hepatitis B vaccine. In early 1990, Wu Lee Yan-Hwa turned to hepatitis C virus research from hepatitis B and found that the core protein of the hepatitis C virus can inhibit hepatitis B virus replication, and further discovered the possible carcinogenic mechanism of the hepatitis C core protein. The follow-up team conducted in-depth research and discovered the interaction between the core protein of the hepatitis C virus and the important proteins and regulatory factors in the host cell. In addition, the team has published many outstanding results in the research of the RNA helicase DDX3 and the oncogene YB-1. .

In 1994, Yu Ming-Whei and Wang Tzu-Nai, Liao Yun-Fan, Lin Teng-Yin, Chen Chien-Jen published a joint research on multiple risk factors for hepatitis B surface antigen cirrhosis. The research showed a positive correlation between smoking, drinking, and eating preserved foods and cirrhosis.

Yeh Shiou-Hwei is a distinguished professor of the College of Medicine, Graduate Institute of Microbiology at National Taiwan University. She proved that men are more susceptible to liver cancer and discovered and confirmed that the targeted drug therapy for liver cancer, Sorafenib and its chemical derivatives, through the liver-specific protein molecule (SHP1), specifically inhibit the hepatic androgen signal transmission pathway, without affecting the male reproductive system. Therefore, it can reduce the occurrence of male liver cancer, but still retain the function of normal male fertility.